Trial
NCT03146871
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Intervention
Azacitidine
Why stopped
Lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-08